Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Heart Failure II: Pathophysiology01:29

Heart Failure II: Pathophysiology

1.6K
Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
1.6K
Cardiomyopathy III: Hypertrophic Cardiomyopathy01:29

Cardiomyopathy III: Hypertrophic Cardiomyopathy

812
Hypertrophic cardiomyopathy, or HCM, is an autosomal dominant genetic disorder characterized by asymmetric left ventricular hypertrophy without ventricular dilation. It is more common in men and is typically diagnosed in young, athletic adults.EtiologyHCM is primarily genetic and is caused by mutations in genes encoding sarcomeric proteins. Researchers have identified over 1400 mutations across at least 11 different genes. Among these, the most frequently occurring mutations are found in the...
812
Mitral Regurgitation I: Introduction01:20

Mitral Regurgitation I: Introduction

1.2K
Mitral regurgitation is characterized by the backward circulation of blood from the left ventricle to the left atrium during systole, a phase of the cardiac cycle when the heart contracts and pumps blood out of the chambers. This abnormal flow occurs primarily due to the dysfunction of the mitral valve or its supporting structures, which include the mitral leaflets, chordae tendineae, annulus, and papillary muscles.Etiology and Mechanisms:Primary Mitral Regurgitation: This type arises from...
1.2K
Mitral Stenosis I: Introduction01:22

Mitral Stenosis I: Introduction

1.6K
Mitral Valve Stenosis (MVS) is a heart condition where the mitral valve narrows, impeding blood circulation from the left atrium to the left ventricle. The etiology and pathophysiology of this condition are multifaceted, leading to a cascade of cardiovascular complications.Causes of Mitral Valve StenosisRheumatic Heart Disease: It is the main cause of mitral valve stenosis, particularly in developing nations. This condition arises from rheumatic fever, an inflammatory illness resulting from...
1.6K
Cellular Adaptation II: Hypertrophy01:26

Cellular Adaptation II: Hypertrophy

5
Hypertrophy is the increase in the size of individual cells, resulting in the enlargement of a tissue or organ. Unlike hyperplasia, which involves an increase in cell number, hypertrophy is characterized by an increase in cell volume. This process often occurs in response to higher functional demand or hormonal stimulation, leading to the production of more structural proteins and organelles, thereby enhancing the cells' work capacity.There are two primary types of hypertrophy:...
5
Pathophysiology of Heart Failure01:17

Pathophysiology of Heart Failure

4.8K
Heart failure (HF) is a progressive syndrome involving ventricles that leads to inadequate cardiac output. It can be classified based on location and output or ejection fraction. Ejection fraction (EF) is an essential measurement in the diagnosis and surveillance of HF. Reduced EF corresponds to systolic heart failure (HFrEF). However, HF with preserved ejection fraction (HFpEF) is becoming increasingly prevalent. Also known as diastolic HF, this form of HF is related to aging. The...
4.8K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Pitfalls in Echocardiography: Superior Aortic Recess Pericardial Effusion Mimicking Ascending Aorta Dissection.

Journal of cardiovascular echography·2026
Same author

Immunogenicity in Fabry Disease: Current Issues, Coping Strategies, and Future Directions.

Biomedicines·2026
Same author

The role of renal denervation for the treatment of hypertension in patients with chronic kidney disease: a position paper of the Italian Society of Nephrology.

Journal of nephrology·2025
Same author

Clinical Efficacy and Real-World Effectiveness of Fabry Disease Treatments: A Systematic Literature Review.

Journal of clinical medicine·2025
Same author

The Inflammatory Pathogenetic Pathways of Fabry Nephropathy and Agalopathy: <italic>GLA</italic> Variant Induction of Endoplasmic Reticulum Stress.

Nephron·2025
Same author

Pathogenesis of Organ Damage in Fabry Disease: The AGALopathy Pathogenetic Pathway.

Journal of the American Society of Nephrology : JASN·2025

Related Experiment Video

Updated: Apr 19, 2026

Evaluation of Right Ventricular Function in Experimental Models of Pulmonary Arterial Hypertension
10:03

Evaluation of Right Ventricular Function in Experimental Models of Pulmonary Arterial Hypertension

Published on: June 27, 2025

1.0K

[Parathormone and left ventricular hypertrophy].

Carlo Massimetti, Paola Achilli, Giordano Zampi

    Giornale Italiano Di Nefrologia : Organo Ufficiale Della Societa Italiana Di Nefrologia
    |December 16, 2014
    PubMed
    Summary

    Secondary hyperparathyroidism (sHPT) significantly predicts left ventricular hypertrophy (LVH) in hemodialysis patients. Treating sHPT with vitamin D receptor activators (VDRAs) may reduce LVH progression.

    More Related Videos

    Technique of Minimally Invasive Transverse Aortic Constriction in Mice for Induction of Left Ventricular Hypertrophy
    08:34

    Technique of Minimally Invasive Transverse Aortic Constriction in Mice for Induction of Left Ventricular Hypertrophy

    Published on: September 25, 2017

    25.9K
    Biventricular Assessment of Cardiac Function and Pressure-Volume Loops by Closed-Chest Catheterization in Mice
    08:21

    Biventricular Assessment of Cardiac Function and Pressure-Volume Loops by Closed-Chest Catheterization in Mice

    Published on: June 15, 2020

    5.2K

    Related Experiment Videos

    Last Updated: Apr 19, 2026

    Evaluation of Right Ventricular Function in Experimental Models of Pulmonary Arterial Hypertension
    10:03

    Evaluation of Right Ventricular Function in Experimental Models of Pulmonary Arterial Hypertension

    Published on: June 27, 2025

    1.0K
    Technique of Minimally Invasive Transverse Aortic Constriction in Mice for Induction of Left Ventricular Hypertrophy
    08:34

    Technique of Minimally Invasive Transverse Aortic Constriction in Mice for Induction of Left Ventricular Hypertrophy

    Published on: September 25, 2017

    25.9K
    Biventricular Assessment of Cardiac Function and Pressure-Volume Loops by Closed-Chest Catheterization in Mice
    08:21

    Biventricular Assessment of Cardiac Function and Pressure-Volume Loops by Closed-Chest Catheterization in Mice

    Published on: June 15, 2020

    5.2K

    Area of Science:

    • Nephrology
    • Cardiology
    • Endocrinology

    Background:

    • Secondary hyperparathyroidism (sHPT) is common in hemodialysis (HD) patients.
    • Left ventricular hypertrophy (LVH) is a significant complication in HD patients.
    • The relationship between sHPT and LVH requires further investigation.

    Purpose of the Study:

    • To examine the association between secondary hyperparathyroidism (sHPT) and left ventricular hypertrophy (LVH) in hemodialysis (HD) patients.
    • To assess the impact of parathyroid hormone (PTH) levels and vitamin D receptor activator (VDRA) treatment on LVH progression.

    Main Methods:

    • Retrospective study of 60 HD patients with two echocardiograms over 12-16 months.
    • Patients categorized into three groups based on PTH levels and VDRA treatment response.
    • Correlation and multiple regression analyses used to evaluate PTH and left ventricular mass index (LVMi).

    Main Results:

    • Parathyroid hormone (PTH) levels strongly correlated with left ventricular mass index (LVMi) (r=0.714, P<0.001).
    • Higher baseline PTH levels (>300 pg/ml) were associated with significantly higher LVMi compared to lower levels (<300 pg/ml).
    • LVH progression was observed in patients with increasing PTH levels, while LVH regression occurred in patients with reduced PTH after VDRA treatment.

    Conclusions:

    • Parathyroid hormone plays a crucial role in the development and progression of LVH in HD patients.
    • Treatment of sHPT with VDRAs can lead to regression or slowed progression of LVH.
    • Management of sHPT is important for cardiovascular health in HD patients.